62577-90-6

Basic information

• Product Name: 4-Cyclopropoxy-benzoic acid
• Synonyms: 4-Cyclopropoxy-benzoic acid;4-Cyclopropyloxybenzoic Acid
• CAS NO: 62577-90-6
• Molecular Formula: C₁₀H₁₀O₃
• Molecular Weight: 178.1846
• EINECS: -0
• Mol File: 62577-90-6.mol

Chemical Properties

• Melting Point: 161-162 °C
• Boiling Point: 325.5±15.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3(Predicted)
• PKA: 4.47±0.10(Predicted)
• CAS DataBase Reference: 4-Cyclopropoxy-benzoic acid(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Cyclopropoxy-benzoic acid(62577-90-6)
• EPA Substance Registry System: 4-Cyclopropoxy-benzoic acid(62577-90-6)

Safety Data

• Hazardous Substances Data: 62577-90-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropyloxybenzoic Acid is used as a key intermediate for the preparation of imidazobenzazepine derivatives, which act as DGAT-1 inhibitors. These inhibitors are crucial in the treatment of diabetes and obesity, as they help regulate the synthesis of triglycerides and modulate lipid metabolism, thus contributing to the management of these metabolic disorders.

Upstream product

• 38380-85-7 1-bromo-4-(cyclopropyloxy)benzene 
• 456-22-4 4-Fluorobenzoic acid 
• 16545-68-9 cyclopropanol 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 223690-01-5 methyl 4-cyclopropoxybenzoate 
• 1005-61-4 4-bromophenyl vinyl ether 
• 106-41-2 4-bromo-phenol 
• 124-38-9 carbon dioxide 
• 120-47-8 Ethyl 4-hydroxybenzoate 
• 4333-56-6 cyclopropyl bromide 

Downstream Products

• 1310817-10-7 ethyl 1-[[4-(cyclopropoxy)benzoyl]amino]cyclopropanecarboxylate 
• 1310817-16-3 4-(cyclopropoxy)-N-[1-(5,6-dihydro-4H-imidazo[1,2-a][1]benzazepin-4-ylcarbamoyl)cyclopropyl]benzamide 
• 1310817-14-1 1-[[4-(cyclopropoxy)benzoyl]amino]cyclopropanecarboxylic acid 
• 1005487-45-5 4-cyclopropoxybenzoyl chloride 

Relevant articles and documents

S1P1 AGONIST AND APPLICATION THEREOF

The present invention relates to a class of tricyclic compounds and an application thereof as a sphingosine 1-phosphate type 1 (S1P1) receptor agonist. The invention specifically relates to a compound represented by formula (II), and a tautomer and pharmaceutically acceptable salt of same.

One-Pot Approach for S N Ar Reaction of Fluoroaromatic Compounds with Cyclopropanol

A novel method for preparing aromatic compounds containing cyclopropoxy via nucleophilic aromatic substitution reaction (S N Ar) of fluoroaromatic compounds with cyclopropanol under relatively mild conditions is presented. As compared to the ap

PPAR AGONISTS AND METHODS OF USE THEREOF

Provided herein are deuterated compounds and compositions useful in increasing PPAR5 activity. The compounds and compositions provided herein are useful for the treatment of PPAR5 related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION

The present invention relates to the use of piperazinones for inhibiting arenavirus infection in humans, other mammals, or in cell culture, to methods of treating arenavirus infection such as Lassa, Bolivian, Argentine, Venezuelan, Brazilian, Chapare and

PPAR AGONISTS

Provided herein are compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

Inhibitors of Diacylglycerol Acyltransferase

This invention provides compounds of formula I: or a pharmaceutically acceptable salt thereof; as well as a method for treating obesity, a method for treating diabetes, and a pharmaceutical composition.

N,N'-Heptamethylenebis(4-methoxybenzamide)

4-(Q-O)-4'-R1 -N,N'-alkylenebis(benzamides), N,N'-alkylenebis(3,4-methylenedioxybenzamides) or N,N'-alkylenebis[4-(lower-alkoxy)benzamides], having endocrinological properties, where Q is lower-alkyl, lower-alkoxyalkyl, lower-alkenyl, halo-lower-alkyl, halo-lower-alkenyl, lower-cycloalkyl, phenyl and BN-(lower-alkyl) where BN is di-(lower-alkyl)amino or a saturated N-heteromonocyclic radical having from five to seven ring atoms and alkylene has at least five carbon atoms between its two connecting linkages and R1 is Q-O-, hydrogen, lower-alkoxy, lower-alkyl, halo, benzyloxy, hydroxy, di-(lower-alkyl)amino, nitro, amino or trihalomethyl are prepared preferably by reacting the appropriate diamine or N-(aminoalkyl)-benzamide with two or one molar equivalents, respectively, of the appropriate benzoyl halide.